Most interestingly, high ZNF217 expression levels confer resistance to ET in ER+ breast cancer cell lines, and ZNF217 expression silencing is associated with reversion of such resistance (Nguyen et al., 2014). The gene discussed is ZNF217; the disease is breast carcinoma.